Transgenomic (TBIO) Reports Q4 Loss of $0.77/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Transgenomic Provides Financial and Business Update
April 15, 2015 4:05 PM EDTConference Call to Be Held at 5:00 PM Eastern Time Today
OMAHA, Neb.--(BUSINESS WIRE)-- Transgenomic, Inc. (NASDAQ: TBIO) today provided a business update and financial review for the year ended December 31, 2014.
In 2014, we made good progress in building a foundation for renewed growth at Transgenomic, said Paul Kinnon, Transgenomics President and Chief Executive Officer. We executed on the development of Multiplexed ICE COLD-PCR (MX-ICP) in 2014, setting the stage for validation of the product in 2015 and its launch in the second quarter. A key recent... More
